IGC Pharma, Inc.
IGCDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
9dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
IGC Earnings Report
EPS Est: $-0.02 | FQ end 2026-06
IGC-AD1-Active Phase 2 Est. Readout
Primary completion for IGC-AD1-Active trial (NCT05543681) in Alzheimer Disease
SourceHow IGC's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IGC-AD1-Active | Phase 2 | Alzheimer Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in IGC Pharma, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in IGC Pharma, Inc.'s (IGC) pipeline across Phase 2. Its lead program is IGC-AD1-Active (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IGC Pharma, Inc.'s next FDA catalyst?→
IGC Pharma, Inc.'s (IGC) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IGC biotech catalysts?→
Add IGC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IGC Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.